The Cancer Cell Biology (CCB) Program is comprised of 62 members from 23 departments. Since the past funding cycle the research base of the Cancer Cell Biology has nearly doubled from $15,046,494 to $22,406,120 total annual direct research support, of which $3,643,399 is from the NCI. Over this last grant period, there were 558 publications of Cancer Cell Biology Program members, of which 3.9% are intraprogrammatic and 24.2% are inter-programmatic . Members of the Cancer Cell Biology program are nationally recognized experts in a spectrum of disciplines unified by the goal of furthering our understanding of the process of oncogenesis at the cellular and molecular level, In order to develop new strategies for the treatment and prevention of cancer. Program investigators have advanced cancer biology in the areas of deregulated growth, proliferation, and cell death pathways: chromatin remodeling;cancer stem cells;embryonic signaling pathways;and tumor invasion programs. The bench-based research carried out by our program members has led to translational studies and clinical trials using novel, targeted approaches to cancer therapy which may afford significant advantages over currently available therapeutics.
The mission of the Cancer Cell Biology Program is to bring together scientists studying basic aspects of cancer biology, including mechanisms controlling initial tumor formation, expansion, invasion, metastasis, and maintenance. By working to identify key molecules that regulate various aspects of tumor biology, an important goal of the Program is to help find new or improved approaches to cancer prevention and treatment.
|Pinskey, Justine M; Franks, Nicole E; McMellen, Alexandra N et al. (2017) Neuropilin-1 promotes Hedgehog signaling through a novel cytoplasmic motif. J Biol Chem 292:15192-15204|
|Skolarus, Ted A; Metreger, Tabitha; Hwang, Soohyun et al. (2017) Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials 18:181|
|Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668|
|Mann, J E; Hoesli, R; Michmerhuizen, N L et al. (2017) Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer 8:332-344|
|Maj, Tomasz; Wang, Wei; Crespo, Joel et al. (2017) Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18:1332-1341|
|Zhang, Jie; Feng, Shumei; Su, Wenmei et al. (2017) Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep 7:42819|
|Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188|
|Birkeland, Andrew C; Foltin, Susan K; Michmerhuizen, Nicole L et al. (2017) Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncol 68:5-8|
|Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852|
|Friese, Christopher R; Harrison, Jordan M; Janz, Nancy K et al. (2017) Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer 123:1925-1934|
Showing the most recent 10 out of 1355 publications